Data as of Mar 10
| +0.02 / +0.22%|
The 3 analysts offering 12-month price forecasts for Supernus Pharmaceuticals Inc have a median target of 12.00, with a high estimate of 13.00 and a low estimate of 12.00. The median estimate represents a +30.43% increase from the last price of 9.20.
The current consensus among 4 polled investment analysts is to Buy stock in Supernus Pharmaceuticals Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.